Hsbc Holdings PLC Crispr Therapeutics Ag Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

A detailed history of Hsbc Holdings PLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Hsbc Holdings PLC holds 15,070 shares of CRSP stock, worth $721,551. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,070

Previous 26,865 43.9%

Holding current value

$721,551

Previous $1.45 Million 51.17%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$44.62 - $62.75 $526,292 - $740,136	-11,795 Reduced 43.9%	15,070 $708,000
Q2 2024 Aug 12, 2024	BUY	$51.17 - $68.18 $1.37 Million - $1.83 Million	26,865 New	26,865 $1.45 Million
Q2 2022 Aug 11, 2022	SELL	$43.23 - $73.83 $359,846 - $614,560	-8,324 Reduced 41.89%	11,548 $715,000
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $70,902 - $105,626	1,333 Added 7.19%	19,872 $1.26 Million
Q4 2021 Feb 11, 2022	BUY	$70.09 - $111.29 $390,751 - $620,441	5,575 Added 43.0%	18,539 $1.4 Million
Q3 2021 Nov 12, 2021	BUY	$110.2 - $156.64 $200,894 - $285,554	1,823 Added 16.36%	12,964 $1.47 Million
Q2 2021 Aug 13, 2021	SELL	$100.84 - $161.89 $206,116 - $330,903	-2,044 Reduced 15.5%	11,141 $1.8 Million
Q1 2021 May 14, 2021	BUY	$110.72 - $210.04 $222,657 - $422,390	2,011 Added 18.0%	13,185 $1.61 Million
Q4 2020 Feb 12, 2021	BUY	$79.67 - $173.23 $525,981 - $1.14 Million	6,602 Added 144.4%	11,174 $1.71 Million
Q3 2020 Nov 12, 2020	BUY	$78.5 - $100.64 $142,870 - $183,164	1,820 Added 66.13%	4,572 $390,000
Q2 2020 Aug 14, 2020	SELL	$38.5 - $76.05 $929,428 - $1.84 Million	-24,141 Reduced 89.77%	2,752 $202,000
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $905,756 - $1.68 Million	26,893 New	26,893 $1.12 Million

Others Institutions Holding CRSP

# of Institutions

491

Shares Held

58M

Call Options Held

1.1M

Put Options Held

1.9M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.74B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Crispr Therapeutics Ag Transaction History